Addex Therapeutics (ADXN) has announced that it will present promising results from its novel GABAB positive allosteric modulator (PAM) chronic cough program at the Thirteenth London International Cough Symposium on July 19.
In guinea pig models of chronic cough, the candidate GABAB PAM demonstrated a significant and dose-dependent reduction in cough frequency induced by citric acid, starting from a minimal efficacious dose of 1 mg/kg. Additionally, the treatment increased cough latency and showed no signs of tolerance even after sub-chronic administration.
When compared to the GABAB agonist baclofen, the selective GABAB PAM exhibited a wider safety margin by effectively maintaining a separation between its minimal efficacious dose and the dose associated with side effects. Baclofen, while possessing antitussive properties, is constrained in clinical use due to its short half-life and central nervous system side effects, such as sedation.
